University of California

Medimmune Limited

Jianlong Lou

James David Marks

Jody Lynn Baron

Ping Tsui

Stephen L Nishimura

Yifan Cheng

Yanli Wu

Anthony Cormier

Isin N Geren

Naoki Takasaka

Shenping Wu

Saburo Ito

Melody G Campbell

Stephen Nishimura

Maria Consuelo Garcia

Ali Razai

Peter Amersdorfer

Jody L Baron

Lynne Murray

James Marks

Antibodies that bind to αvβ8 are provided.

Antibodies that bind integrin αvβ8 and uses thereof

New antibodies and methods of use are described.

Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy

Antibodies that bind to &#x3b1;&#x3bd;&#x3b2;8 are provided.

Antibodies that bind integrin AVB8 and uses thereof

Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy

Provided is an antibody that specifically binds human &#x3b1;v&#x3b2;&#x3b2; and blocks binding of TGFp peptide to &#x3b1;v&#x3b2;8, wherein the antibody binds to the specificity determining loop (SDL) of human &#x3b2;8. In some embodiments, the antibody further binds to one, two, or all three of the human av-head domain, the al helix of human &#x3b2;8, or the al helix of human &#x3b2;8. In some embodiments, the antibody is humanized or chimeric. In some embodiments, the antibody is linked to a detectable label. Also provided is a method of enhancing an immune response in a human individual, comprising administering a sufficient amount of the antibody to the individual, thereby enhancing an immune response. Also provided are pharmaceutical compositions comprising the anti-&#x3b1;v&#x3b2;&#x3b2; antibodies or antigen-binding molecules thereof.

Neutralizing antibodies to the &#x3b1;v&#x3b2;8 integrin complex for immunotherapy

This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Antibodies that neutralize botulinum neurotoxins

This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

The present invention relates to &#x3b1;v&#x3b2;8 antagonists, anti-&#x3b1;v&#x3b2;8 antibodies or immunoconjugates for reducing TGF&#x3b2; activation in an individual. Further provided are compositions comprising one of the &#x3b1;v&#x3b2;8 antagonists, anti-&#x3b1;v&#x3b2;8 antibodies or immunoconjugates, methods for using the compositions, and related subject matter.

Integrin &#x3b1;v&#x3b2;8 neutralizing antibody

Provided herein are antibodies with high affinity for the &#x3b2;8 subunit of &#x3b1;v&#x3b2;8.

Antibodies that bind integrin alpha-V beta-8

Integrin &#x3b1;-V&#x3b2;8 neutralizing antibody

This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

Growing community of inventors

San Bruno, CA, United States of America

Jianlong Lou